AMS Capital’s Genomic Health, Inc. GHDX Stock Holding History

AMS Capital’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12,020	Closed	-$844K	–	52
2018 Q3	$844K	Buy	+12,020	New	+$703K	0.69%	30

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AMS Capital's GHDX Position: Q4 2018 in Review

AMS Capital sold out of Genomic Health, Inc. (GHDX) in Q4 2018, closing a stake of 12,020 shares — an estimated $844K sold.

AMS Capital first reported a position in GHDX in Q3 2018 and held it in 1 quarter. The position peaked at $844K in Q3 2018. 228 funds tracked by Wall St. Rank hold GHDX as of Q4 2018.

AMS Capital reported no remaining Genomic Health, Inc. position as of Q4 2018 after selling out during the quarter.
AMS Capital sold 12,020 Genomic Health, Inc. shares in Q4 2018, an estimated $844K.
AMS Capital first reported a position in Genomic Health, Inc. in Q3 2018 and held it in 1 quarter.
AMS Capital's Genomic Health, Inc. position peaked at $844K in Q3 2018.
228 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2018.

Based on AMS Capital's 13F filing for Q4 2018, filed 29 Jan 2019.